Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | SCD | O00767 | 4/20 | 0.56 |
| ▸ | SNCA | P37840 | 1/20 | 0.55 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.54 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532955 | 0.88 | CASP3 (0.65) | HTTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17251803 | 0.88 | CASP3 (0.65) | HTTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6058049 | 0.86 | NPC1 (0.63) | HTTNPC1RAB9ALCKSMN1; SMN2 | |
| SCHEMBL31398557 | 0.84 | HSD17B10 (0.67) | HTTNPC1RAB9ASMN1; SMN2SCD | |
| SCHEMBL6057846 | 0.83 | HSD17B10 (0.56) | HTTNPC1RAB9ALCKSMN1; SMN2 | |
| SCHEMBL21681925 | 0.83 | RAB9A (0.68) | HTTNPC1RAB9ALCKSMN1; SMN2 | |
| SCHEMBL21682154 | 0.83 | SCD (0.70) | HTTNPC1RAB9ALCKSMN1; SMN2 | |
| SCHEMBL6058431 | 0.81 | HTT (0.61) | HTTNPC1RAB9ALCKALDH1A1 | |
| SCHEMBL21681916 | 0.81 | MAP3K5 (0.69) | HTTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6058400 | 0.81 | SMN1; SMN2 (0.58) | HTTNPC1RAB9ALCKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1037632-B1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-01-11 | — | — | EP | claimed |
| US-6825355-B2 | FOR THERAPY OF IMMUNOLOGIC DISORDERS SUCH AS TRANSPLANT REJECTION, RHEUMATOID ARTHRITIS. MULTIPLE SCLEROSIS, INFLAMMATORY BOWEL DISEASE, LUPUS, GRAFT VS. HOST DISEASE | BRISTOL-MYERS SQUIBB CO. | 2004-11-30 | — | — | US | claimed |
| US-20020123484-A1 | Benzothiazole protein trosine kinase inhibitors | DAS JAGABNDHU (US) | 2002-09-05 | — | — | US | claimed |
| US-6825355-B2 | FOR THERAPY OF IMMUNOLOGIC DISORDERS SUCH AS TRANSPLANT REJECTION, RHEUMATOID ARTHRITIS. MULTIPLE SCLEROSIS, INFLAMMATORY BOWEL DISEASE, LUPUS, GRAFT VS. HOST DISEASE | BRISTOL-MYERS SQUIBB CO. | 2004-11-30 | — | — | US | disclosed |
| EP-1037632-A4 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1037632-A1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999024035-A1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123484-A1 | Benzothiazole protein trosine kinase inhibitors | TXK, LTK, JAK2 | HTT 1325/4885NPC1 2700/4885RAB9A 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.